We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AptarGroup, Inc. (ATR - Free Report) reported third-quarter 2023 adjusted earnings per share of $1.39, beating the Zacks Consensus Estimate of $1.28. The bottom line increased 46.3% year over year from 95 cents (including comparable exchange rates).
On a reported basis, earnings per share were $1.26 compared with the year-ago quarter’s 81 cents.
Total revenues increased 6.7% year over year to $893 million in the reported quarter. The reported figure surpassed the Zacks Consensus Estimate of $890 million. Core sales, excluding currency and acquisition effects, improved 2% year over year due to strong volume growth in the pharma and beauty segments. We expected core sales to be up 5.5% in the quarter.
Operational Update
Cost of sales rose 3.7% year over year to $567 million. Gross profit improved 12.3% year over year to $326 million. The gross margin expanded to 36.5% in the reported quarter compared with the prior-year quarter’s 34.7%.
Selling, research, development and administrative expenses increased 2% year over year to $138 million. Adjusted operating income increased 35.9% year over year to $131 million. The adjusted operating margin was 14.6% in the reported quarter, up from the year-ago quarter’s 11.5%. Adjusted EBITDA rose 25.8% year over year to $193 million in the third quarter.
AptarGroup, Inc. Price, Consensus and EPS Surprise
Total revenues in the Pharma segment increased 13.3% year over year to $389 million. The reported figure missed our estimate of $394 million. Adjusted operating income in the quarter rose 29.1% year over year to $108 million. We predicted a quarterly adjusted operating income of $107 million.
Total revenues in the Beauty segment increased 6.9% year over year to $324 million. Our estimation for the segment’s revenues was $316 million. Operating income improved 19.6% year over year to $20 million in the third quarter. The reported figure missed our operating income prediction of $21.5 million.
Total revenues in the Closures segment decreased 5.6% year over year to $180 million. We estimated revenues to be $179 million in the quarter. Operating income was $15 million in third-quarter 2023, reflecting growth of 40.6% from the year-ago quarter. Our prediction for the quarter was $13 million.
Financial Performance
AptarGroup reported cash and cash equivalents of $152 million as of Sept 30, 2023, up from $142 million as of Dec 31, 2022. The company generated $173 million of cash flow from operations in the third quarter of 2023 compared with $130 million in the prior-year quarter. As of Sept 30, 2023, the long-term debt was $680 million, down from $1,053 million as of Dec 31, 2022.
Outlook
AptarGroup estimates fourth-quarter 2023 adjusted earnings per share of $1.06-$1.14.
Price Performance
Shares of the company have gained 24.9% in the past year against the industry’s fall of 1.9%.
Image Source: Zacks Investment Research
Zacks Rank and Other Key Picks
AptarGroup currently carries a Zacks Rank #2 (Buy).
The Zacks Consensus Estimate for Brady’s 2023 earnings per share is pegged at $3.62. The consensus estimate for 2023 earnings has moved 13% north in the past 60 days and suggests year-over-year growth of 9.9%. The company has a trailing four-quarter average earnings surprise of 7.2%. Shares of BRC rallied 17.7% in the last year.
Applied Industrial has an average trailing four-quarter earnings surprise of 15%. The Zacks Consensus Estimate for AIT’s 2023 earnings is pegged at $9.13 per share, which indicates year-over-year growth of 2%. Estimates have moved up 2% in the past 60 days. The company’s shares gained 27% in the last year.
Emerson has an average trailing four-quarter earnings surprise of 7.4%. The Zacks Consensus Estimate for EMR’s 2023 earnings is pegged at $4.45 per share. The consensus estimate for 2023 earnings has moved 1% north in the past 60 days. EMR’s shares gained 5.9% in the last year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
AptarGroup (ATR) Q3 Earnings Beat Estimates, Revenues Rise Y/Y
AptarGroup, Inc. (ATR - Free Report) reported third-quarter 2023 adjusted earnings per share of $1.39, beating the Zacks Consensus Estimate of $1.28. The bottom line increased 46.3% year over year from 95 cents (including comparable exchange rates).
On a reported basis, earnings per share were $1.26 compared with the year-ago quarter’s 81 cents.
Total revenues increased 6.7% year over year to $893 million in the reported quarter. The reported figure surpassed the Zacks Consensus Estimate of $890 million. Core sales, excluding currency and acquisition effects, improved 2% year over year due to strong volume growth in the pharma and beauty segments. We expected core sales to be up 5.5% in the quarter.
Operational Update
Cost of sales rose 3.7% year over year to $567 million. Gross profit improved 12.3% year over year to $326 million. The gross margin expanded to 36.5% in the reported quarter compared with the prior-year quarter’s 34.7%.
Selling, research, development and administrative expenses increased 2% year over year to $138 million. Adjusted operating income increased 35.9% year over year to $131 million. The adjusted operating margin was 14.6% in the reported quarter, up from the year-ago quarter’s 11.5%. Adjusted EBITDA rose 25.8% year over year to $193 million in the third quarter.
AptarGroup, Inc. Price, Consensus and EPS Surprise
AptarGroup, Inc. price-consensus-eps-surprise-chart | AptarGroup, Inc. Quote
Segmental Performances
Total revenues in the Pharma segment increased 13.3% year over year to $389 million. The reported figure missed our estimate of $394 million. Adjusted operating income in the quarter rose 29.1% year over year to $108 million. We predicted a quarterly adjusted operating income of $107 million.
Total revenues in the Beauty segment increased 6.9% year over year to $324 million. Our estimation for the segment’s revenues was $316 million. Operating income improved 19.6% year over year to $20 million in the third quarter. The reported figure missed our operating income prediction of $21.5 million.
Total revenues in the Closures segment decreased 5.6% year over year to $180 million. We estimated revenues to be $179 million in the quarter. Operating income was $15 million in third-quarter 2023, reflecting growth of 40.6% from the year-ago quarter. Our prediction for the quarter was $13 million.
Financial Performance
AptarGroup reported cash and cash equivalents of $152 million as of Sept 30, 2023, up from $142 million as of Dec 31, 2022. The company generated $173 million of cash flow from operations in the third quarter of 2023 compared with $130 million in the prior-year quarter. As of Sept 30, 2023, the long-term debt was $680 million, down from $1,053 million as of Dec 31, 2022.
Outlook
AptarGroup estimates fourth-quarter 2023 adjusted earnings per share of $1.06-$1.14.
Price Performance
Shares of the company have gained 24.9% in the past year against the industry’s fall of 1.9%.
Image Source: Zacks Investment Research
Zacks Rank and Other Key Picks
AptarGroup currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks from the Industrial Products sector are Brady (BRC - Free Report) , Applied Industrial Technologies (AIT - Free Report) and Emerson Electric Co. (EMR - Free Report) . BRC currently sports a Zacks Rank #1 (Strong Buy), and AIT and EMR have a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Brady’s 2023 earnings per share is pegged at $3.62. The consensus estimate for 2023 earnings has moved 13% north in the past 60 days and suggests year-over-year growth of 9.9%. The company has a trailing four-quarter average earnings surprise of 7.2%. Shares of BRC rallied 17.7% in the last year.
Applied Industrial has an average trailing four-quarter earnings surprise of 15%. The Zacks Consensus Estimate for AIT’s 2023 earnings is pegged at $9.13 per share, which indicates year-over-year growth of 2%. Estimates have moved up 2% in the past 60 days. The company’s shares gained 27% in the last year.
Emerson has an average trailing four-quarter earnings surprise of 7.4%. The Zacks Consensus Estimate for EMR’s 2023 earnings is pegged at $4.45 per share. The consensus estimate for 2023 earnings has moved 1% north in the past 60 days. EMR’s shares gained 5.9% in the last year.